| Ytd | -29.41% | |
| 1y | -29.41% |
| Open | 0.82 | Prev Close | 0.79 | Low | 0.81 | High | 0.82 | Mkt Cap | 22.89M |
| Vol | 96.61K | Avg Vol | 512.80K | EPS | -1.77 | P/E | -0.46 | Forward P/E | N/A |
| Beta | 1.39 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.91 | 200-d Avg | 1.22 | 1yr Est | 0.00 |
RNTX News
Data support ongoing Phase 2 “RENEW” trial First-in-human clinical study produced measurable reducti
AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (
Rein Therapeutics Inc. (RNTX) Shareholder/Analyst Call Prepared Remarks Transcript
Rein Therapeutics Inc. (RNTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimis
16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) First patient
Total gross proceeds increased to $57.5 million Offering consisted solely of common stock Proceeds e
Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates,
AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company")
Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries
Shares of Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report) traded up 1.6% during trading on F
Rein Therapeutics Inc. (NASDAQ: RNTX - Get Free Report)'s stock price traded down 0.8% during mid-da
Rein Therapeutics (NASDAQ:RNTX) stock is trading higher on Monday, with a session volume of 41.2 mil
AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopha
AUSTIN, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a bioph
AUSTIN, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceut
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopha
Meeting adjourned to Wednesday, July 23, 2025 at 9:00 a.m. Eastern Time AUSTIN, Texas , June 24, 202
Rein Therapeutics has paused patient enrollment and dosing in a mid-stage trial of its lung disease
Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosi
Presentations further support the dual mechanism of LTI-03 and the development of Cav1-related pepti
RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmon